Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
British Journal of Cancer, Feun LG et al.
Arginine–depleting therapy with pegylated arginine deiminase (ADI–PEG20) is safe and the drug is only efficacious in melanoma patients whose tumour has negative argininosuccinate synthetase (ASS) expression. Argininosuccinate synthetase tumour positivity is associated with drug resistance and tumour progression.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.